title: Darbepoetin Administration in Term and Preterm Neonates.
abstract: Erythropoiesis-stimulating agents (ESAs) such as erythropoietin have been studied as red cell growth factors in preterm and term infants for more than 20 years. Recent studies have evaluated darbepoetin (Darbe, a long-acting ESA) for both erythropoietic effects and potential neuroprotection. We review clinical trials of Darbe in term and preterm infants, which have reported significant erythropoietic uses and neuroprotective effects. ESAs show great promise in decreasing or eliminating transfusions, and in preventing and treating brain injury in term and preterm infants.
authors.affiliation: Division of Neonatology, Department of Pediatrics, University of Utah, 296 Chipeta Way, Salt Lake City, UT 84105, USA.
authors.forename: Shrena
authors.initials: S
authors.lastname: Patel
authors.affiliation: Division of Neonatology, Department of Pediatrics, University of New Mexico, MSC10 5590, 1 University of New Mexico, Albuquerque, NM 87131-0001, USA. Electronic address: rohls@salud.unm.edu.
authors.forename: Robin K
authors.initials: RK
authors.lastname: Ohls
mesh_terms: D000068256:Darbepoetin alfa / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D006397:Hematinics / Q000008:administration & dosage; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy*; D000066829:Neuroprotection / Q000187:drug effects*; D016896:Treatment Outcome
chemical_list: D006397:Hematinics; D000068256:Darbepoetin alfa
keywords: Anemia; Darbepoetin; Erythropoiesis-stimulating agents; Neurodevelopment; Neuroprotection; Transfusions